Background: Eosinophilic airway inflammation is common in asthma patients and appears to be associated with severe exacerbations and loss of asthma control. Objective: To describe the resource utilization and clinical characteristics of patients with eosinophilic asthma. Design: Asthma patients >= 18 years with >= 1 blood eosinophil count in secondary care (South West Finland) during 2003. 2013 were included. Clinical characteristics (age, lung function, body mass index, and comorbidities) and asthma-related resource utilization (hospital admissions, outpatient visits, and emergency room [ER] visits) were retrieved. Resource utilization rates were compared for patients with blood eosinophil 300 cells/mu L, using adjusted negative binomial r...
Background: Recent studies have demonstrated an association between high blood eosinophil counts and...
Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are ...
Background: Mepolizumab is an anti–IL-5 antibody approved for the treatment of severe eosinophilic a...
Background: Eosinophilic airway inflammation is common in asthma patients and appears to be associat...
BACKGROUND: Blood eosinophil counts correlate with exacerbations, but there is a lack of consensus o...
Background: blood eosinophil measurement is essential for the phenotypic characterization of patient...
Background: Some reports have suggested that the clinical and economic burdens of asthma are associa...
BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inh...
BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inh...
BACKGROUND: Asthma is a disease that can be separated into different phenotypes and endotypes based ...
Summary: Background: In asthma, the airway inflammatory phenotype influences clinical characteristic...
Background: Severe asthma is a complex disease with heterogeneous features and involves type 2 airwa...
Word count: 3032.International audienceRATIONALE: There is increasing interest regarding asthma hete...
Abstract Background Stratification of patients with severe asthma by blood eosinophil counts predict...
Background: Severe asthma is a complex amalgam of phenotypes and comorbidities. Most novel therapies...
Background: Recent studies have demonstrated an association between high blood eosinophil counts and...
Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are ...
Background: Mepolizumab is an anti–IL-5 antibody approved for the treatment of severe eosinophilic a...
Background: Eosinophilic airway inflammation is common in asthma patients and appears to be associat...
BACKGROUND: Blood eosinophil counts correlate with exacerbations, but there is a lack of consensus o...
Background: blood eosinophil measurement is essential for the phenotypic characterization of patient...
Background: Some reports have suggested that the clinical and economic burdens of asthma are associa...
BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inh...
BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inh...
BACKGROUND: Asthma is a disease that can be separated into different phenotypes and endotypes based ...
Summary: Background: In asthma, the airway inflammatory phenotype influences clinical characteristic...
Background: Severe asthma is a complex disease with heterogeneous features and involves type 2 airwa...
Word count: 3032.International audienceRATIONALE: There is increasing interest regarding asthma hete...
Abstract Background Stratification of patients with severe asthma by blood eosinophil counts predict...
Background: Severe asthma is a complex amalgam of phenotypes and comorbidities. Most novel therapies...
Background: Recent studies have demonstrated an association between high blood eosinophil counts and...
Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are ...
Background: Mepolizumab is an anti–IL-5 antibody approved for the treatment of severe eosinophilic a...